Abstract:Copyright © 2021 Massachusetts Medical Society. Pulmonary hypertension is a syndrome characterized by marked remodeling of the pulmonary vasculature and a progressive rise in the pulmonary vascular load, leading to hypertrophy and remodeling of the right ventricle. Death results from right ventricular failure if pulmonary hypertension is left untreated. Pulmonary hypertension is currently defined hemodynamically by a mean pulmonary arterial pressure of higher than 20 mm Hg at rest, as measured by right heart catheterization.1 Precapillary pulmonary hypertension due to pulmonary vascular disease is further defined by an elevation in pulmonary vascular resistance of at least 3 Wood units (WU), in contrast to isolated postcapillary pulmonary hypertension, in which the pulmonary vascular resistance is less than 3 WU and the elevation in the mean pulmonary arterial pressure is due to elevated filling pressures on the left side of the heart. The several forms of pulmonary hypertension are categorized into five clinical groups (Fig. 1). This review focuses on the relatively rare form of pulmonary arterial hypertension (group 1). Immense progress has been achieved in gaining an understanding of the mechanisms, natural history, and genetic features of pulmonary arterial hypertension and in establishing targeted therapy. A full appreciation of the pathophysiology of the syndrome is important, since the diagnosis requires a thorough clinical investigation to rule out other, more common forms of pulmonary hypertension, for which treatment of the underlying disease should be the primary goal. The first anatomical description of pulmonary hypertension is credited to von Romberg.2 However, it is the advent of human right heart catheterization, first performed by Forssmann on himself in 1929,3 that led to a flurry of physiological observations on the heart and pulmonary circulation by Cournand and Richards in the 1940s. The three investigators received the Nobel Prize in Physiology or Medicine in 1956 for their seminal work. In his illuminating Nobel Lecture, Richards noted that, as a result of their collective work, ì many forms and degrees of failure were defined, and their responses to treatment measured.î 4 In 1951, Dresdale, a disciple of Cournand and Richards, and colleagues presented the first case series of patients with pulmonary hypertension of unknown cause, defined as ì primary pulmonary hypertension.î 5 Greater awareness of the disease developed in the 1960s, after an epidemic of primary pulmonary hypertension that was associated with the use of the appetite suppressant aminorex.6 This prompted the World Health Organization to convene a first meeting of pulmonary hypertension experts in 1973, to standardize the clinical and pathological nomenclature of primary pulmonary hypertension, the first attempt at an organized classification.7 The first and second meetings about pulmonary hypertension were separated by 25 years, but thereafter the World Symposium on Pulmonary Hypertension (WSPH) was convened every 5 years. The meetings brought further refinement to the classification of pulmonary hypertension, with five distinct groups Darren B. Taichman, M.D., Ph.D., Editor

Referrals for pulmonary hypertension rise by 21% in five years, audit finds

Self-reported physician practices in pulmonary arterial hypertension: Diagnosis, assessment, and referral

Incidence of Pulmonary Hypertension in the Echocardiography Referral Population

Pulmonary Hypertension Surveillance--united States, 1980-2002.

Referral to pulmonary rehabilitation and palliative care services in people with idiopathic pulmonary fibrosis in England, 2010–2019

Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review

Characterizing pulmonary rehabilitation referrals from primary care

The diagnostic journey of pulmonary arterial hypertension patients: results from a multinational real-world survey

Retrospective on global pulmonary hypertension clinical trials: 1999-2021

Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.

Pulmonary arterial hypertension: updates and perspective with newer therapies

Health care utilisation in patients with mild pulmonary hypertension - EVIDENCE-PAH UK study

Clinical characteristics of pulmonary hypertension patients who underwent right heart catheterization in Thailand: 5-year retrospective single-centre study

Risk stratification and medical therapy of pulmonary arterial hypertension

[Classification, diagnosis and treatment status of pulmonary hypertension from 2012 to 2019: a single center study in Yunnan province]

Risk assessment and real-world outcomes in chronic thromboembolic pulmonary hypertension: insights from a UK pulmonary hypertension referral service

“SEEK, AND YOU WILL FIND” - IMPLICATIONS OF PULMONARY HYPERTENSION DIAGNOSIS AND TREATMENT OF PATIENT WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND LEFT HEART FAILURE

Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension

Pulmonary Arterial Hypertension.

Hyperuricemia in patients with pulmonary hypertension: A study in a tertiary care center

Nationwide trends of balloon pulmonary angioplasty and pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension (2012–2019)